Imperial College London
Alternate

Emeritus ProfessorMyraMcClure

Faculty of Medicine, Department of Infectious Disease

Emeritus Professor of Retrovirology
 
 
 
//

Contact

 

+44 (0)20 7594 3902m.mcclure

 
 
//

Location

 

456Medical SchoolSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Elliot:2019:cid/ciy426,
author = {Elliot, ER and Wang, X and Singh, S and Simmons, B and Vera, JH and Miller, RF and Fitzpatrick, C and Moyle, G and McClure, M and Boffito, M},
doi = {cid/ciy426},
journal = {Clinical Infectious Diseases},
pages = {87--95},
title = {Increased dolutegravir peak concentrations in people living with HIV aged 60 and over and analysis of sleep quality and cognition},
url = {http://dx.doi.org/10.1093/cid/ciy426},
volume = {68},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Background: Demographic data show an increasingly aging HIV population worldwide. Recent concerns over dolutegravir-related neuropsychiatric toxicity have emerged, particularly amongst older HIV patients. We describe the pharmacokinetics (PK) of dolutegravir (DTG) 50mg once daily in people living with HIV (PLWH) aged 60 and older. Additionally, to address the call for prospective neuropsychiatric toxicodynamic data, we evaluate changes in sleep quality and cognitive function after switching to abacavir (ABC)/lamivudine (3TC)/DTG, over 6 months in this population. Methods: PLWH aged≥60years with HIV-RNA<50copies/mL on any non-DTG based antiretroviral combination were switched to ABC/3TC/DTG. On day 28, 24-hour PK sampling was undertaken. Steady-state PK parameters were compared to a published historical control population aged≤50years. Six validated sleep questionnaires and neurocognitive (Cogstate®) testing were administered pre-switch and over 180 days (NCT02509195). Results: Forty-three participants were enrolled; 40 completed the PK phase. Overall, five discontinued (two due adverse events, both sleep related, 4.6%). DTG maximum concentration (Cmax) was significantly higher in patients≥60 versus controls (GM 4246ng/mL versus 3402ng/mL, p=0.005). In those who completed day 180 (n=38), sleep impairment was higher at day 28 (PSQI median global score 5.0 versus 6.0 p=0.02) but not at day 90 or 180. Insomnia, daytime function, fatigue test scores did not change statistically over time. Conclusion: DTG Cmax was significantly higher in older PLWH. Our data provides clinicians with key information on the safety of prescribing DTG in older PLWH.
AU  - Elliot,ER
AU  - Wang,X
AU  - Singh,S
AU  - Simmons,B
AU  - Vera,JH
AU  - Miller,RF
AU  - Fitzpatrick,C
AU  - Moyle,G
AU  - McClure,M
AU  - Boffito,M
DO  - cid/ciy426
EP  - 95
PY  - 2019///
SN  - 1058-4838
SP  - 87
TI  - Increased dolutegravir peak concentrations in people living with HIV aged 60 and over and analysis of sleep quality and cognition
T2  - Clinical Infectious Diseases
UR  - http://dx.doi.org/10.1093/cid/ciy426
UR  - https://www.ncbi.nlm.nih.gov/pubmed/29771285
UR  - http://hdl.handle.net/10044/1/60661
VL  - 68
ER  -
Download